Small Molecules in Oncology

This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK intera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Format: Elektronisch E-Book
Sprache:Englisch
Veröffentlicht: Cham : Springer International Publishing, 2018.
Ausgabe:3rd ed. 2018.
Schriftenreihe:Recent Results in Cancer Research, 211
Schlagworte:
ISBN:9783319914428
ISSN:0080-0015 ;
Online-Zugang: Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

MARC

LEADER 00000nam a22000005i 4500
003 SK-BrCVT
005 20220618102915.0
007 cr nn 008mamaa
008 180801s2018 gw | s |||| 0|eng d
020 |a 9783319914428 
024 7 |a 10.1007/978-3-319-91442-8  |2 doi 
035 |a CVTIDW14063 
040 |a Springer-Nature  |b eng  |c CVTISR  |e AACR2 
041 |a eng 
245 1 0 |a Small Molecules in Oncology  |h [electronic resource] /  |c edited by Uwe M. Martens. 
250 |a 3rd ed. 2018. 
260 1 |a Cham :  |b Springer International Publishing,  |c 2018. 
300 |a VIII, 276 p. 34 illus., 19 illus. in color.  |b online resource. 
490 1 |a Recent Results in Cancer Research,  |x 0080-0015 ;  |v 211 
500 |a Medicine  
505 0 |a Erlotinib -- Lapatinib -- Sorafenib -- Regorafenib -- Crizotinib -- Cabozantinib -- Vemurafenib -- Trametinib -- Everolimus -- Vismodegib -- Larotrectinib -- Palbociclib -- Taselisib -- Cobimetinib -- Lenvatinib -- Afatinib -- Olaparib -- Gefitinib -- Ceritinib. . 
516 |a text file PDF 
520 |a This book, written by respected experts, discusses in detail the latest developments in targeted oncology therapy using small molecules. It covers a wide range of small molecules, including tyrosine kinase inhibitors, mTOR, MEK, PARP, and multikinase inhibitors, as well as cell cycle and NTRK interacting agents. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book is the third edition of Small Molecules in Oncology, but has now been divided into two volumes, with the other volume focusing specifically on small molecules in hematology. . 
650 0 |a Oncology . 
650 0 |a Cancer research. 
856 4 0 |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-3-319-91442-8  |y Vzdialený prístup pre registrovaných používateľov 
910 |b ZE11343 
919 |a 978-3-319-91442-8 
974 |a andrea.lebedova  |f Elektronické zdroje 
992 |a SUD 
999 |c 243154  |d 243154